NEW YORK (GenomeWeb) – Craig-Hallum Capital Group today upgraded shares of Cepheid to a Buy rating, based on recent deals with Quest Diagnostics and Laboratory Corporation of America and an expansion of its product portfolio.

Analyst Bill Bonello upgraded the shares from a previous Hold rating and raised the price target to $75 per share from $52.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.